Skip to main content

Ibane Abasolo Olaortua

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

Ibane Abasolo Olaortua

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Biologist
Bioquímica
Cross-departmental services

I am a researcher, head of the Drug Delivery & Targeting (DDT) group and a member of the Clinical Biochemistry Service. Our research is aimed at improving the treatment of various diseases through the use of nanoparticles of natural or synthetic origin that selectively deliver treatments to the cells that need them. I am also a member of the Department of Biochemistry and Molecular Biology of the Autonomous University of Barcelona and I participate in the VHIR Master's Degree in Translational Biomedicine where I coordinate the internship module.

I graduated in Biochemistry and Biology at the University of Navarra. During my doctorate in the laboratories of Dr. Alfonso Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern University, Chicago, USA), I studied the role of a peptide hormone, adrenomedullin, in cancer. Later, I continued my postdoctoral training in the group of Prof. F.X. Real (IMIM, Barcelona), where I acquired extensive experience in experimental mouse models, from the generation of transgenic models to their molecular characterization, an experience that I completed with a specialization in molecular imaging techniques at the IAT-PRBB.
Since 2007, I have been working at Vall d'Hebron, where I started as a post-doctoral researcher and head of the technology platform called Functional Validation & Preclinical Research (FVPR)-U20 ICTS. Since 2021 I am also the leader of the Drug Delivery & Targeting group at VHIR and at the CIBER for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).
My research, and that of my group, seeks to improve the treatment of different diseases through the use of nanoparticles and hydrogels. These systems are specifically designed to protect the therapeutic agent and cause it to be released where and when it is needed. Noteworthy, we work at all steps of the preclinical development, from the design of the nanomaterial, to its synthesis, characterization and testing in experimental models of the disease.
I am currently leading two European projects (SafeNMT and Mimic-key) and two Spanish projects (PI21/00930 and NanoDireCT), focused on the treatment of cancer (breast, pancreas and prostate) and lysosomal storage diseases (Fabry, Sanfilippo and pycnodysostosis).

Projects

Advancing on drug delivery-combined targeted treatments against human breast cancer and Leukemia (Oncotarget/Nano)

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 28300
Reference: EUI2008-0170
Duration: 01/03/2009 - 01/03/2011

Ministerio de Ciencia

Development of nanomedicines for enzymatic replacement therapy in Fabry disease

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Fundació La Marató de TV3
Funding: 214925
Reference: MARATV3/2010/101230
Duration: 03/02/2011 - 31/12/2014

POLYSFERA: Nanocápsulas poliméricas para liberación controlada y dirigida de fármacos antitumorales

IP: Ibane Abasolo Olaortua
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 505955
Reference: IPT-090000-2010-0001
Duration: 22/06/2010 - 21/06/2013

Ministerio de Ciencia

Activación de vías dependientes del oncogen BRAF en la tumorogénesis y metástasis del cáncer colorectal en modelos in vivo

IP: Simon Schwartz Navarro
Collaborators: Ibane Abasolo Olaortua
Funding agency: Instituto de Salud Carlos III
Funding: 219252
Reference: PI080771
Duration: 01/01/2009 - 30/06/2012

Related news

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.

Related professionals

Aroa Ruiz Muñoz

Aroa Ruiz Muñoz

Research technician
Cardiovascular Diseases
Read more
Mar Fomaguera Padrós

Mar Fomaguera Padrós

Epidemiology and Public Health
Read more
Daniel Bravo Nieto

Daniel Bravo Nieto

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Daniel Carranza Rojo

Daniel Carranza Rojo

Senior researcher
Pediatric Neurology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.